Rising Pharmaceuticals Launches Mesalamine Suppository
24 June 2019 - - US-based drugmaker Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, has launched in the US and begun commercial shipment of a generic version of Canasa, (mesalamine) Suppository, in 1,000 mg strength, the company said.
Mesalamine Suppositories had US sales of approximately USD 263m for the 12 months ending March 2019, according to IMS Health.
Mesalamine Suppositories are indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. The product should be taken only as prescribed.
Rising Pharmaceuticals, as the exclusive distributor for its development partner, Pharmaceutical Sourcing Partners, Inc., who recently received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application, will launch the product immediately.
Rising is a supplier of generic medicines in the US, and the launch of Mesalamine Suppositories, adds to the company's robust and expanding human pharmaceutical franchise.
Rising Pharmaceuticals sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers.
Currently, Rising has over 125 approved and commercial products in the US market and an additional 82 products pending launch or in development, representing a combined USD 12.5bn in addressable market value.


Related Headlines